Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder

  • Abeona Therapeutics Inc ABEO announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). 
  • The VIITAL study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds.
  • EB-101 significantly improved wound healing vs. control at six months.
  • In addition to meeting the co-primary pain endpoint, in a post-hoc analysis of the EB-101 treated severe wounds, a mean pain reduction from baseline at six months of 5.70 was observed, compared to a mean pain reduction of 3.51 for all treated randomized and non-randomized wounds.
  • EB-101 was well-tolerated, with no serious treatment-related adverse events observed, consistent with past clinical experience. 
  • Concurrently, Abeona announced a private placement of 7.07 million shares, pre-funded warrants exercisable for 543,933 shares, and accompanying warrants to purchase 7.61 million shares for gross proceeds of $35 million.
  • The offering price for each share and accompanying warrant was $4.60, and for each pre-funded warrant and an accompanying warrant was $4.59. 
  • Each accompanying warrant has an exercise price of $4.75 per share.
  • Price Action: ABEO shares are down 25.80% at $3.31 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFinancingOfferingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!